| Kim, Do Young |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
NCT05808335: A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) |
|
|
| Recruiting | 2a | 32 | RoW | Standard of care | ImmuneMed, Inc. | Chronic Hepatitis B | 03/24 | 12/24 | | |
NCT05908916: Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 51 | RoW | AtezoBev with combined radiotherapy | Yonsei University | Hepatocellular Carcinoma | 07/25 | 07/26 | | |
IDADOX, NCT06114082: TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 128 | RoW | IDA-TACE, Conventional TACE using idarubicin chemoemulsion, DOX-TACE, Conventional TACE using doxorubicin chemoemulsion | Seoul National University Hospital, Guerbet | Hepatocellular Carcinoma, Liver Cancer | 12/25 | 06/26 | | |
| Active, not recruiting | 1/2 | 53 | Europe, RoW | MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib | Medivir | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases | 12/24 | 06/25 | | |
NCT06712108: Observational Study of Double Cord Blood Transplant |
|
|
| Recruiting | N/A | 40 | RoW | tranplant | Seoul National University Hospital | Adult Double Unit Cord Blood Transplant | 03/30 | 03/30 | | |
| Recruiting | N/A | 396 | RoW | Home-based care | Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, DongGuk University, Kyung Hee University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital | Malignant Neoplasm, Home Care Services, Quality of LIfe, Unplanned Hospitalization | 12/26 | 12/26 | | |
| Seo, Kyoung Yul |
NCT04775303: A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING) |
|
|
| Recruiting | 4 | 90 | RoW | Cyclosporine 0.1% (Ikervis®) eye drop | Yonsei University | Moderate to Severe Dry Eye | 01/22 | 01/22 | | |
| Pak, Hui-Nam |
NCT03840291: Resolution of Thrombi in Left Atrial Appendage With Edoxaban |
|
|
| Completed | 4 | 36 | RoW | Edoxaban, Lixiana® | Keimyung University Dongsan Medical Center, Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company | Atrial Fibrillation, Left Atrial Appendage Thrombosis | 10/23 | 08/24 | | |
NCT06179849: Artificial Intelligence-enabled Large-scale Electrocardiogram Feature Extraction and Exploring Association Between the Extracted Features and Mortality, Stroke or Various Health Outcome of Interest |
|
|
| Not yet recruiting | N/A | 3000000 | RoW | | Yonsei University | Health Status(Death, Stroke Etc) | 12/25 | 12/25 | | |
NCT02176616: Evaluation of Proper Radiofrequency Catheter Ablation Strategy for the Patients Who Were Changed to Paroxysmal Atrial Fibrillation From Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 120 | RoW | linear ablation, pulmonary vein isolation | Yonsei University | Atrial Fibrillation | 02/24 | 06/24 | | |
NCT03920917: Cryoballoon Pulmonary Vein Isolation vs. Radiofrequency Pulmonary Vein Isolation With Additional Right Atrial Linear Ablation for Paroxysmal Atrial Fibrillation: Prospective Randomized Trial (CRAPAF Trial) |
|
|
| Recruiting | N/A | 330 | RoW | Cryoballoon Pulmonary Vein isolation, Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation | Yonsei University | Paroxysmal Atrial Fibrillation | 03/24 | 03/24 | | |
UTMOST AF II, NCT03912324: Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation |
|
|
| Recruiting | N/A | 220 | RoW | Unipolar voltage subtraction map guided PV isolation group, CT myocardial thickness map guided PV isolation group, Empirical PV isolation group | Yonsei University | Paroxysmal Atrial Fibrillation | 04/25 | 04/25 | | |
NCT04223310: Clinical Usefulness of Virtual Antiarrhythmic Drug Test in Patients With Recurred AF After Catheter Ablation(CUVIA-AF3) |
|
|
| Recruiting | N/A | 300 | RoW | Virtual AAD TEST group, Empirical AAD group | Yonsei University | Atrial Fibrillation | 12/24 | 12/24 | | |
NCT03682887: Cryoballoon Pulmonary Vein Isolation vs. Cryoballoon Pulmonary Vein Isolation With Additional Right Atrial Linear Ablation for Persistent Atrial Fibrillation (CRARAL Trial) |
|
|
| Active, not recruiting | N/A | 195 | RoW | Cryoballoon PV isolation group, Cryoballoon PV isolation with Additional RA linear ablation group | Yonsei University | Persistent Atrial Fibrillation | 09/25 | 09/25 | | |
NCT04632550: Giant Left Atrium Atrial fibrillatioN CathEter Ablation, Posterior Box Isolation vs. Dallas Lesion Set |
|
|
| Not yet recruiting | N/A | 480 | RoW | Circumferential pulmonary vein isolation(CPVI) group, Posterior box isolation(POBI) group, POBI+Anterior linear ablation(AL) group | Yonsei University | Atrial Fibrillation | 10/25 | 10/25 | | |
NCT04942171: EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy(EMOTICON Trial) |
|
|
| Not yet recruiting | N/A | 320 | RoW | Atrial fibrillation catheter ablation group, Medical therapy group | Yonsei University | Atrial Fibrillation | 02/26 | 02/26 | | |
CUVIA-AF II, NCT02558699: Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation |
|
|
| Recruiting | N/A | 110 | RoW | physician's personal experience, Virtual rotor mapping | Yonsei University | Paroxysmal Atrial Fibrillation | 12/27 | 12/27 | | |
NCT02138695: The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study |
|
|
| Recruiting | N/A | 3100 | RoW | | Yonsei University | Atrial Fibrillation | 02/29 | 02/29 | | |
AI-PAFA, NCT04997824: Artificial Intelligence Guided Patient Selection for Atrial Fibrillation Catheter Ablation: Randomized Clinical Trial ( Trial) |
|
|
| Recruiting | N/A | 1000 | RoW | Artificial Intelligence-based atrial fibrillation catheter ablation, Medical Therapy | Yonsei University | Atrial Fibrillation | 06/31 | 06/31 | | |
| Ahn, Myung-Ju |
ATTLAS, NCT03991403: Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC |
|
|
| Active, not recruiting | 3 | 228 | RoW | Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab, Carboplatin, Paclitaxel, Carboplatin or cisplatin | Samsung Medical Center | Non-small Cell Lung Cancer | 03/23 | 03/24 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
NCT03257124: Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS |
|
|
| Active, not recruiting | 2 | 80 | RoW | AZD9291, Osimertinib | Samsung Medical Center | Non-Small Cell Lung Cancer With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors | 08/19 | 12/21 | | |
| Active, not recruiting | 2 | 401 | Europe, Japan, US, RoW | Durvalumab, MEDI4736 (Durvalumab), Placebo for Olaparib, Placebo, Olaparib, AZD2281 (Olaparib), Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin | AstraZeneca | Non-small Cell Lung Cancer NSCLC | 01/21 | 09/25 | | |
|
|
NCT03450967: Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC |
|
|
| Active, not recruiting | 2 | 31 | RoW | Durvalumab Plus Tremelimumab | Samsung Medical Center | Head and Neck Squamous Cell Carcinoma | 06/21 | 03/22 | | |
NCT03614364: Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma |
|
|
| Active, not recruiting | 2 | 41 | RoW | nanoxel, herzuma | Samsung Medical Center | Salivary Duct Carcinoma | 09/22 | 08/23 | | |
NCT04967417: Pembrolizumab with Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients with Asymptomatic Brain Metastases |
|
|
| Completed | 2 | 13 | RoW | Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel, Carboplatin, Pembrolizumab | Samsung Medical Center | Non-small Cell Lung Cancer | 06/24 | 12/24 | | |
BLOSSOM, NCT04563871: Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) |
|
|
| Completed | 2 | 73 | RoW | 80mg Osimertinib, Tagrisso 80mg | Samsung Medical Center, AstraZeneca | Non-small Cell Lung Cancer (NSCLC) | 10/23 | 10/23 | | |
| Active, not recruiting | 2 | 366 | Europe, Canada, Japan, US, RoW | osimertinib, savolitinib, placebo | AstraZeneca, Hutchison MediPharma | Carcinoma | 08/24 | 05/25 | | |
|
|
NCT05463224: Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients |
|
|
| Active, not recruiting | 2 | 150 | RoW | Lazertinib group | Myung-Ju Ahn | NSCLC | 03/25 | 07/25 | | |
NCT05727410: Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma |
|
|
| Recruiting | 2 | 50 | RoW | nivolumab, docetaxel, cisplatin Group | Myung-Ju Ahn | High-grade Salivary Gland Carcinoma | 08/26 | 08/26 | | |
NCT06106802: Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment |
|
|
| Not yet recruiting | 2 | 47 | RoW | Lazertinib, Tepotinib | Samsung Medical Center | Non-Small Cell Lung Cancer Metastatic | 09/29 | 09/29 | | |
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 110 | US, RoW | EU101 | Eutilex | Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer | 09/25 | 12/25 | | |
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 258 | Europe, US, RoW | TAK-186, MVC-101 | Takeda | Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer | 09/25 | 11/26 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
NCT05798026: A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy |
|
|
| Recruiting | 1 | 15 | RoW | EU103 | Eutilex | Solid Tumor | 04/25 | 12/25 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 244 | Canada, Japan, US, RoW | GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448 | GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics | Neoplasms | 09/25 | 09/25 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
OPTIMUS, NCT04909164: The Prospective Non-randomized Case-control Study from Real-world Lung Cancer Patients |
|
|
| Recruiting | N/A | 1500 | RoW | Immunnotherapy group, Cytotoxic chemotherapy group | Samsung Medical Center, National Evidence-Based Healthcare Collaborating Agency | Non-small Cell Lung Cancer (NSCLC) | 01/25 | 12/25 | | |
NCT02546895: Prospective Registration of Head and Neck Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | chart review, surveys | Samsung Medical Center | Head and Neck Cancer | 12/25 | 12/25 | | |
| Yoon, Hong Man |
NCT04394585: Effect of Smart Phone App-based Human Coaching Program in Gastrectomized Patients |
|
|
| Recruiting | N/A | 180 | RoW | smart phone app based human coaching program | National Cancer Center, Korea | Stage I Gastric Cancer | 11/22 | 12/23 | | |
NCT04674501: Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON) |
|
|
| Recruiting | N/A | 200 | RoW | Cardiac evaluation and blood sampling | Yonsei University | Patients Who Receive Thoracic Irradiation | 12/22 | 12/22 | | |
| Recruiting | N/A | 247 | RoW | Sentinel basin dissection | National Cancer Center, Korea | Sentinel Lymph Node, Early Gastric Cancer | 12/24 | 12/24 | | |
NCT03681535: Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma |
|
|
| Active, not recruiting | N/A | 241 | Europe, Japan, US, RoW | Radiation Therapy | Duke University | Diffuse Large B Cell Lymphoma | 08/25 | 08/28 | | |
NCT04740346: Survival Rates and Quality of Life According to Follow-up Period After Gastrectomy for Gastric Cancer (STOFOLUP) |
|
|
| Recruiting | N/A | 886 | RoW | Computed tomography, Chest X-ray, and blood test | National Cancer Center, Korea, Korea Health Industry Development Institute | Gastric Cancer, Recurrence, Quality of Life | 06/26 | 06/26 | | |
| Cha, Bong Yun |
| Completed | 4 | 51 | RoW | Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin | Yonsei University | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases, Fatty Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypoglycemic Agents, Physiological Effects of Drugs, Sodium-Glucose Cotransporter 2 Inhibitors, Pioglitazone, Molecular Mechanisms of Pharmacological Action, Empagliflozin, Thiazolidinediones | 06/22 | 06/22 | | |
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients |
|
|
| Recruiting | 4 | 2862 | RoW | Enavogliflozin, Dapagliflozin or Empagliflozin | Yonsei University | Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases | 09/29 | 12/30 | | |
| Kwon, So Young |
ADAPT, NCT04782375: Safely Discontinue Antiviral Treatment in Patients with Chronic Hepatitis B |
|
|
| Active, not recruiting | 4 | 140 | RoW | Stop group, discontinue antiviral treatment | Asan Medical Center | Hepatitis B, Chronic | 08/24 | 01/25 | | |
ATTACH, NCT04780204: Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels |
|
|
| Active, not recruiting | 4 | 600 | RoW | Treatment, Tenofovir alafenamide | Asan Medical Center, National Evidence-Based Healthcare Collaborating Agency | Hepatitis B, Chronic | 01/27 | 12/27 | | |
ATTENTION, NCT03753074: Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines |
|
|
| Active, not recruiting | 4 | 780 | RoW | Tenofovir Alafenamide, Vemlidy | Young-Suk Lim, Samsung Medical Center, Kyunghee University Medical Center, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul National University Hospital, Ulsan University Hospital, Konkuk University Medical Center, Kyungpook National University Hospital, Korea University Guro Hospital, Seoul St. Mary's Hospital, Kaohsiung Medical University, Chang Gung Memorial Hospital, E-DA Hospital, Taitung Mackay Memorial Hospital, National Cheng-Kung University Hospital, Chi Mei Medical Hospital, Chiayi Christian Hospital, St. Martin De Porress Hospital, Dalin Tzu Chi General Hospital, Taichung Veterans General Hospital, China Medical University Hospital, Seoul National University Bundang Hospital | Chronic Hepatitis b | 12/31 | 12/31 | | |
NCT05805865: Efficacy of Eco-Friendly Toothpaste Tablets Versus Conventional Toothpaste Using PI and GI Index |
|
|
| Completed | N/A | 40 | US | Toothpaste Tablet, Conventional Toothpaste | Loma Linda University | Gingival Inflammation | 01/23 | 01/23 | | |
NCT06673342: Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake |
|
|
| Not yet recruiting | N/A | 100 | NA | Nutritional Counseling, Stephan's Curve | Loma Linda University | Dental Cavity, Caries,Dental | 01/26 | 01/27 | | |
| Joung, Bo Young |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Park, Sungha |
NCT04331691: Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension |
|
|
| Completed | 4 | 118 | RoW | Spironolactone, Amiloride | Yonsei University | Resistant Hypertension | 05/24 | 05/24 | | |
NCT03540992: Development of Diagnostic and Treatment Strategy for Resistant Hypertension |
|
|
| Recruiting | N/A | 780 | RoW | | Yonsei University | Resistant Hypertension | 02/23 | 02/23 | | |
NCT02003781: Individualized Prevention Strategy for High Risk Patients in Cardiovascular Disease: Prospective Cohort Study (Cardiovascular and Metabolic Disease Etiology Research Center - HIgh Risk Cohort) CMERC-HI |
|
|
| Recruiting | N/A | 4000 | RoW | | Yonsei University | High Risk Cardiovascular Disease Patients | 10/23 | 10/23 | | |
NCT05494138: Nutriomics and Artificial Intelligence Nutrition Obesity Cohort |
|
|
| Recruiting | N/A | 650 | RoW | | Yonsei University | Obesity | 08/26 | 08/41 | | |
NCT04749927: Deep Learning of Retinal Photographs and Atherosclerotic Cardiovascular Disease |
|
|
| Recruiting | N/A | 2400 | RoW | | Yonsei University | Cardiovascular Disease | 10/29 | 10/29 | | |
| Park, Kwankyu |
NCT05320913: Pericapsular Nerve Group (PENG) Block Combined With Periarticular Multimodal Drug Injection (PMDI) Versus Isolated PMDI for Pain Management After Total Hip Arthroplasty: a Randomized Controlled Trial |
|
|
| Recruiting | N/A | 58 | RoW | Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI), PENG + PMDI block, isolated periarticular multimodal drug injection (PMDI), Isolated PMDI block | Yonsei University | Total Hip Arthroplasty, Postoperative Pain | 12/23 | 12/23 | | |
| Wekken, Anthonie Van der |
NVALT28, NCT04597671: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC |
|
|
| Active, not recruiting | 3 | 170 | Europe | Durvalumab, Imfinzi, low-dose PCI, Prophylactic Cranial Irradiation (PCI) | Association NVALT Studies | Carcinoma, Non-Small-Cell Lung | 12/28 | 12/32 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Lee, Seungkyu |
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy |
|
|
| Recruiting | 3 | 160 | RoW | Brolucizumab 6mg, Beovu | Novartis Pharmaceuticals | Macular Polypoidal Choroidal Vasculopathy (PCV) | 09/25 | 09/25 | | |
PMC403-A01, NCT05953012: Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 36 | RoW | PMC-403, Monotherapy | PharmAbcine, C&R Research, Inc. | Neovascular Age-related Macular Degeneration | 05/24 | 10/25 | | |
